Anthropic launches Claude Science workbench and plans to develop drugs for rare diseases

Anthropic's Claude Science bets on workflow, not a new model, to win over scientists

Anthropic introduced Claude Science on Tuesday, an AI workbench that gives scientists one environment to do computational research, sparing them the hassle of bouncing between databases, pipelines, and tools. To be clear, Anthropic says Claude Science is "not a new AI model and not a more capable model for biology. It runs the same Claude models already available to everyone today (including Claude Opus 4.8), with no special access and no gating." The workbench builds on Anthropic's October 2025 launch of Claude for Life Sciences, which essentially augmented the Claude chatbot by making it better at life sciences tasks. Claude Science is a dedicated place to do that work. he launch, announced Tuesday at an AI for Science briefing, fits into Anthropic's broader push to be more than a model provider and to further own the operating layer for specific industries, the way Claude Code has become the operating layer for software development. Anthropic is increasingly betting its growth on vertical, workflow-level products rather than just raw model capability (which could shape how it competes, and prices, against rivals). Here's how it works: One main AI assistant acts as a kind of project manager for scientists. It connects to more than 60 scientific databases and comes with pre-built toolkits for specific fields, like genomics, protein structure, and chemistry. That assistant can then create sub-assistants to help split up the work, like a project lead delegating tasks to specialists, or hand work off to a custom "expert" assistant that the user has built for their own research. A separate fact-checker AI then double-checks the citations and calculations before anything goes to publication. That fact-check step matters, as more AI-assisted writing leads to fabricated citations and unverifiable stats slipping into papers. That said, it's still the same underlying model checking itself, not an independent source of truth. Claude Science has other ways of ensuring reproducibility. For example, the workbench can generate figures like 3D protein structures and chemistry drawers alongside the code that made them. Each figure includes the "exact code and environment that produced it, a plain-language description of how it was created, and the full message history," according to Anthropic. The process also saves scientists time by allowing them to edit figures in plain language, prompting the agent to edit its own underlying code. Another way Claude Science can save scientists time is by running on the lab's own infrastructure setup rather than sending data off to Anthropic's servers. Early users are already putting this to work. Sean Whalen, a principal scientist in machine learning and functional genomics at Gladstone Institutes, used Claude Science to build a genome browser from scratch in days, according to Anthropic. Allen Institute neuroscientist Jérôme Lecoq used the tool to build a multi-agent computational review pipeline, shaving off years of human work. The Claude Science launch comes a couple of months after OpenAI came at the same problem from a different side. In April, OpenAI released GPT-Rosalind, a specialized model that is fine-tuned for biological reasoning. The difference between the two approaches isn't only about whether a specialized model is necessary -- it also comes down to who gets access, and how fast. Rosalind launched as a research preview limited to qualified enterprise customers in the U.S., gated behind a qualification and safety review. Partners like Amgen, Allen Institute, Moderna, Thermo Fisher, and Novo Nordisk got early access. And then there's Google DeepMind, which is playing a different game entirely. DeepMind actually owns foundational science models like AlphaFold and AlphaGenome, which the other two can only call into as tools. Its Gemini for Science platform also bundles those plus more than 30 life science databases into one skill set. Claude Science is available in beta to anyone on Pro, Max, Team, and Enterprise subscriptions. Anthropic also named Novo Nordisk and Allen Institute as customer case studies, suggesting pharma organizations are already working with multiple AI vendors. Anthropic will also support up to 50 Claude Science projects, providing up to $30,000 in credits: "We are looking for postdoctoral and graduate projects that span domains and explore the boundaries of science, with an early focus on fields across biomedical research. Applications are open through July 15, 2026, with award notifications sent out by July 31. Projects will run from September 1 to December 1, 2026."

Claude Science is Anthropic's newest flagship product

At an event for pharmaceutical executives, biotech founders, and researchers on Tuesday, Anthropic announced Claude Science, a major new product intended to support scientific research in the same way that Claude Code supports software engineering. Like Claude Code, Claude Science can autonomously carry out meaningful work when given concise, high-level instructions, and it has access to tools that make it particularly useful for research in computational biology and drug development. Along with launching and previewing Claude Science, which is now available to all paid Claude subscribers, Anthropic also announced that it will be using the product to pursue some of its own research into drugs for rare, neglected diseases. This is not Anthropic's first foray into AI for science. In October, the company released plug-ins that help Claude make use of scientific software and databases under the heading "Claude for Life Sciences." But unlike this earlier release, Claude Science is a full-featured, standalone product. Anthropic's decision to elevate Claude Science to the same rank as Claude Code and Claude Cowork indicates that the company is taking AI's scientific applications very seriously -- or at least wants to give the impression that it is. "It represents how important this is to our mission that this is right up there with Claude Code and Claude Cowork as the next really significant product that we're releasing," says Eric Kauderer-Abrams, Anthropic's head of life sciences. "Our mission is to develop AI that serves humanity's long-term well-being, and we believe that by far the greatest opportunity to do that is in the life sciences." For the past decade, one company -- Google DeepMind -- has been at the vanguard of AI for science. CEO Demis Hassabis and researcher John Jumper won the Nobel Prize in chemistry for their work on the company's AlphaFold model, and DeepMind has also made major contributions to meteorology, materials science, and a variety of other disciplines. But in the past several months, the fast-advancing frontier of AI progress seems to have left DeepMind in the dust. When it comes to coding, which has become the most lucrative use case for LLMs, DeepMind is stuck playing catch-up. Anthropic is well positioned to take up DeepMind's scientific mantle. Like Hassabis, Anthropic CEO Dario Amodei is a PhD scientist -- unlike OpenAI CEO Sam Altman, who's a businessman through and through. Many scientists are already avid users of tools such as Claude Code. These days, a lot of scientific research involves some amount of coding, but not all scientists are expert software engineers, and so tools like Claude Code can make a huge difference for their productivity. And the company has recently earned a major scientific vote of confidence: Earlier this month, Jumper announced that he is leaving DeepMind for Anthropic. Since agents powered by LLMs, including Anthropic's Opus model series, became capable of useful, independent work in late 2025, scientists have been seeing just how much they can do. In a blog post published on Anthropic's website, the Harvard physicist Matthew Schwartz estimated, on the basis of his work with Claude Code and other Anthropic tools, that the company's Opus 4.5 model is about as capable of executing scientific projects as a second-year graduate student. According to Kauderer-Abrams, Claude Science isn't intended to displace Claude Code and Claude Cowork in scientists' workflows. Instead, it's designed to build on what scientists already find useful about Anthropic's products. For instance, it not only writes code but also helps scientists run their code on powerful computer clusters, which many many scientists need for their work but can be difficult to manage. And it prioritizes reproducibility, so that scientists can trace back the source of any figure or result and check it for accuracy and validity. Though Claude Science could in principle assist with any area of scientific research, it seems designed and marketed as a tool for molecular and cellular biology, and for drug development in particular. It can interface with various tools used in genetics, chemistry, and protein biology, all of which could come in handy for researchers on the hunt for new drugs. During the Tuesday event, Alexander Tarashansky, who led the development of Claude Science, demonstrated how the system could autonomously identify new drug candidates for phenylketonuria, a rare genetic disease. And Anthropic isn't leaving all that work to the pharma companies and university labs that were represented at the event. Armed with Claude Science, it will be pursuing its own research into drug candidates for neglected diseases -- both to help move science forward and to gain a clearer sense of how Claude Science works in the real world. There are obvious humanitarian reasons to prioritize drug development when creating a general-purpose scientific research tool, and AI industry leaders often cite curing disease as a major potential upside of the technology. But it's also notable that pharmaceutical companies have far deeper pockets than academic researchers. Anthropic says it's set to see its first profitable quarter, and if major new contracts with pharmaceutical companies are forthcoming, they could help ensure it stays profitable as the tokenmaxxing craze dies down -- something that's ever more important as an IPO approaches later this year.

Anthropic wants to develop its own drugs

At the event "The Briefing: AI for Science" earlier this week, Anthropic announced Claude Science, a new "AI workbench for scientists" that pulls fragmented tools and datasets into one environment, and generates figures and visuals. Anthropic, already dominating the industry with its popular coding tools and powerful AI models, framed the launch around what it says is AI's potential to "dramatically accelerate the pace of scientific discovery and the development of healthcare interventions," and touted a long list of biotech and pharma customers already using Claude. Anthropic also went a step further, saying it would develop drugs of its own. Head of life sciences Eric Kauderer-Abrams said the company will focus on discovering treatments for "neglected" diseases. AI companies have been eager to court science and pharma customers -- OpenAI, Amazon, Google, and others have their own life sciences tools and platforms. But Anthropic's planned move is one of the most direct public attempts by a major frontier AI company to actually develop drugs itself. It puts it in the unusual position of selling software to other, potentially competing drugmakers. Anthropic joins a broader race that includes AI-first drug companies like Insilico, Google DeepMind spinout Isomorphic Labs, biotech startups, and Big Pharma companies building or buying AI tools of their own. Anthropic has provided very few specific details about what it hopes to accomplish in the drug development space. At the event, Kauderer-Abrams didn't say what the company would do if it finds any promising drug candidates. Anthropic did not respond to The Verge's requests for comment seeking more details, including what diseases it plans to target first and whether it would partner up with other companies for lab work, animal testing, clinical trials, or manufacturing. Experts told The Verge that the uncertainty surrounding Anthropic's plans reflects a broader uncertainty around the AI drug boom itself. "AI drug discovery" can mean many things. It "is a really broad term," explained Namshik Han, a professor at the University of Cambridge and cofounder of AI biotech startup CardiaTec. AI is applied at "every single stage of drug discovery," he said, from finding new compounds and improving them to supporting research, data analysis, clinical trials, and even manufacturing. Every major drug company will be using AI in some way, he said. Matthew Todd, a professor of drug discovery at University College London, echoed the sentiment that AI already pervades drug discovery and research, calling it a "catchall phrase" given its broad array of uses. AI is undoubtedly changing drug development. Han pointed to the numerous initiatives by pharma giants like AstraZeneca, Novo Nordisk, and GSK, and said AI can already help generate possible drug ideas, such as by suggesting new molecules that could interact with parts of the body like cell receptors that are already known to be involved with a particular disease or are targets of existing drugs. Todd said it's immensely useful for speeding up research and helping "road test" new drug ideas. Given Anthropic's work on frontier models, the company would presumably use generative AI to search across vast chemical and biological possibilities and help researchers make connections that would be difficult or slow to find otherwise, potentially suggesting new drug ideas, identifying new disease targets, or finding new uses for existing drugs. But that is still a long way from an AI-designed drug reaching patients. Todd said the field is "a long way off" from an AI-designed drug being approved by regulators for human use. He added that the drug discovery process would not run autonomously, with human input and supervision required throughout. Todd and Han both noted the lack of publicly available, high-quality experimental data, such as how various chemicals behave in the body, could slow drug development efforts as well, stressing that even for well-studied areas of biology there are still large gaps in our understanding of how things work. AI is not positioned to fix many of the slowest parts of drug discovery. Frank von Delft, a professor of structural chemical biology at the University of Oxford and head of protein crystallography at the Oxford Centre for Medicines Discovery, said people are right to get excited about advancing AI models, but they "haven't yet come close to making experiments unnecessary." Drug candidates still have to be tested in the real world for efficacy, toxicity, and whether they have practical properties allowing them to be prepared, stored, and delivered safely as medicines. All of that requires skilled workers, a lot of money, and time, especially clinical work in humans -- a point when many promising drug candidates fail. If Anthropic wants to develop a drug, von Delft said, it is "going to have to spend a lot on experiments." It's possible Anthropic is willing to try. In the last year, the company has been actively hiring biologists and building its own wet labs, and as of writing it has several live applications hiring for life sciences roles. Han said Anthropic has been "actively recruiting" in the area too, adding that several of his academic colleagues had been approached by the company. Without naming names, Han said he thinks Anthropic has successfully hired a few candidates away from Big Pharma and prestigious academic institutions. With all of this complexity, whatever disease Anthropic picks, any payoff is likely a long way away -- at the very least, the better part of a decade, given how long it typically takes a new drug to go through clinical trials. There's "always a big lag time" with testing medicine, Todd said. "It takes time to show experimentally that something's safe." No AI-designed drug has yet made it through clinical trials and FDA approval to reach market. Some AI-developed candidates have entered clinical trials, but it's hard to know how much AI contributed, where in the process it was used, or whether those candidates outperform conventional drugs. AI can speed up part of the search, but drugs still need to prove themselves the old-fashioned way: in slow, methodical experiments that take place in the real world.

Anthropic launches Claude Science in push for pharma revenue

Anthropic has launched an AI product aimed at scientists and pharmaceutical groups, as the $900bn company seeks to expand its enterprise business and boost revenues ahead of its planned initial public offering. The San Francisco-based start-up announced Claude Science on Tuesday, its first product dedicated to scientists, with use cases including rendering 3D protein structures and drug discovery. "We believe that the greatest opportunity to have a scaled positive impact on humanity is through our work in the sciences and in particular in life sciences and healthcare," Eric Kauderer-Abrams, head of life sciences at Anthropic, said in an interview. The release comes amid mounting pressure on Anthropic, as its rapid growth has unsettled markets and intensified concerns about AI's impact on the economy and digital infrastructure. Its Claude Mythos model has spooked governments because of its cyber security capabilities, leading US officials to implement export controls before allowing its release to a limited number of users. Anthropic's Claude Code product, as well as Cowork, an agentic product for non-technical users, has raised alarms in industries including software engineering, consulting and the legal sector for their ability to perform tasks autonomously, fuelling concern that some jobs could be replaced. Claude Science, which runs on existing Claude models, will expand Anthropic's enterprise offerings to target scientists and researchers globally. "There is a really significant overhang of what is possible today relative to what most people are accessing and actually making use of," said Kauderer-Abrams. "The primary purpose of releasing this product is to try to minimise that gap and bring all scientists in every different scientific discipline to the frontier of being able to get the most out of what's possible," he added. AI has become increasingly important to drug research at big pharmaceutical companies. Eli Lilly, maker of popular weight-loss drugs, has invested in Nvidia chips and earlier this year invested in Insilico Medicine, a company specifically focused on AI for drug discovery. Kauderer-Abrams said Claude Science could speed up the pre-development side of drug discovery, such as molecule design, but said the company next wanted to focus on the clinical phase. He added that Anthropic wanted to improve physical lab experiments and was exploring robotics. Anthropic is expected to go public as soon as this year in a listing that could value it at more than $1tn. It closed a $65bn funding round last month at a $900bn valuation, not including the new investment. Claude Science could point investors to another future revenue stream. Anthropic has signed deals with pharma companies and acquired biotech start-up Coefficient Bio in April, which used AI to drive efficiencies in drug discovery and other forms of biological research. Companies including Novo Nordisk have used Claude for drug discovery, clinical documentation and regulatory submissions, as well as to speed up literature synthesis. AstraZeneca has also used Claude to scale research and development. Claude Science is available on paid individual and enterprise subscriptions globally. Science applications are also an important focus for rival OpenAI, which has outlined its ambitions to create an autonomous researcher to advance scientific and technological progress. In April, it launched GPT‑Rosalind, a frontier reasoning model built for research in biology, drug discovery and translational medicine, which focuses on turning medical research into clinical treatments. Additional reporting by Patrick Temple-West in New York

Anthropic launches Claude Science, an AI lab workbench

Claude Science folds a scientist's scattered tools into one app and lets AI agents run analysis end to end, with a reviewer agent to check the citations and maths. It is Anthropic's deepest move into the lab, and a revenue bet ahead of a planned listing. Anthropic has launched Claude Science, an app that pulls a researcher's scattered tools into one place and lets AI agents run large parts of the work. It is the company's biggest push yet into the lab. Anthropic said on June 30, 2026 that Claude Science is now available in beta. The company calls it an AI workbench for scientists. It pulls together the databases, code tools, and compute that researchers juggle every day. An AI agent then moves between them. The pitch targets a real complaint. Scientists work across dozens of databases, each with its own schema. They switch between PubMed, Jupyter, R, and a cluster terminal, and they wrangle file formats that need custom pipelines. Claude Science folds those steps into one environment. It can analyse the literature, run multistep analysis, and refine figures and manuscripts until they are ready to publish. One thing it is not is a new model. Claude Science runs the same Claude models already on sale, including Opus 4.8, with no special access. As TechCrunch put it, the bet is on workflow rather than raw model power. An agent that shows its work At the centre sits a coordinating agent. It draws on more than 60 curated skills and connectors. These are set up for fields such as genomics, proteomics, structural biology, and cheminformatics. The agent can spin up other agents, including specialist ones built by the user. A separate reviewer agent checks citations and calculations, then flags and corrects errors as it goes. Anthropic is leaning hard on reproducibility, the issue that haunts modern science. Every figure arrives with the exact code and environment that produced it. It also carries a plain-language note on how it was made, plus the full message history. A researcher can return months later and trace any result. They can also edit a figure in plain English. Ask the agent to drop gridlines or switch an axis to a log scale, and it rewrites its own code. The reviewer agent matters for a second reason. AI models invent citations and numbers. The system inspects outputs for untraceable figures and references that do not match the code. It is meant to catch its own mistakes before a human does. It runs where the data already lives Claude Science is built to sit on a lab's own machines. It works locally on macOS or Linux, or on a remote box over SSH or an HPC login node. Large jobs, such as folding a protein or running a genomics pipeline, fall to the agent. It drafts a plan and asks before reaching new resources. Then it submits the job to the lab's own cluster, or to a Modal account for compute on demand. The work can scale from one GPU to hundreds. That design also answers a privacy worry. Because the app runs on the lab's infrastructure, large or sensitive datasets never have to leave it. Only the context needed for each step is sent to Claude. Researchers can fork a session to compare two approaches without losing the original. The launch leans on a tie-up with Nvidia. Claude Science uses the chipmaker's BioNeMo Agent Toolkit to reach life-sciences models such as Evo 2, Boltz-2, and OpenFold3. It also draws on more than 60 scientific databases, including UniProt, PDB, and ChEMBL. Nvidia has spread its money and tools across the AI industry, and life sciences is one more front. What the early users say Anthropic points to three beta users. Manifold Bio, which designs medicines that home in on specific tissues, used Claude Science to nominate targets for its latest experiments, weighing surface expression, trafficking, and safety. The firm said the draw was that the app could run the task end to end, with the context of past programmes built in. Jérôme Lecoq, a neuroscientist at the Allen Institute, built a multi-agent template of about 20 custom skills to write long-form reviews. Sub-agents read thousands of papers, pulled the key findings, and stored them in a database, then drafted the review section by section. Lecoq said a single review used to take his team as long as two years. He now has about 10 of them, many running past 100 pages. That number is also the catch. A tool that turns a two-year review into a batch of 10 could speed real synthesis. It could also flood an already strained literature with machine-made papers. Anthropic's answer is the reviewer agent and human checks. Stephen Francis, an epidemiologist at the UCSF Brain Tumor Center, said his glioma analysis ran in about a tenth of the usual time, and that his group checked the results by hand and confirmed they held up. A high-stakes bet on the lab The launch fits a wider plan. Anthropic has framed Claude as a tool that can do real research, not just chat. Science is a market where that claim can be tested. It is also a commercial move. The company is racing to win paying customers ahead of a planned listing, and it has set out huge revenue targets to justify its spending. The timing is awkward in one respect. Anthropic is in a tense standoff with Washington, after the US government moved to block foreign access to its most powerful models. A product built for open scientific collaboration lands in the middle of that fight. Claude Science is in beta on macOS and Linux for Pro, Max, Team, and Enterprise plans, with discounted seats for academic and nonprofit labs. Anthropic will also fund up to 50 research projects with up to $30,000 in credits each. Applications are open until July 15, 2026. The bigger question is whether AI can truly speed discovery, or simply produce more of it. The labs now testing the app will give the first real answer.

Anthropic just released a brand-new Claude Science app for Mac

Anthropic just launched a brand-new desktop app called Claude Science. The new app joins the main Claude app on the Mac, which includes Claude AI, Cowork, and Code. The new Claude Science app arrives in beta today for macOS and Linux. Anthropic says it "runs analyses, searches databases, and traces every step from data wrangling to publication, so you can spend time on science." Claude Science is a public beta app, not a model. It uses the same Claude models your plan includes. What's new is everything around them: the scientific tools, database connections, and compute integrations that let Claude run full analyses on your own infrastructure. Anthropic explains why the new Claude Science app exists: General AI assistants can discuss biology, but they can't run a pipeline, navigate scientific databases, orchestrate cluster jobs, or keep track of what happened in a previous session. Claude Science manages compute environments per specialist, and saves full provenance on every result. The app ships with analysis specialists for genomics, single-cell, proteomics, structural biology, cheminformatics, and more. It can connect natively to 60+ scientific databases and domain-specific open models. Claude Science uses the skills in NVIDIA's BioNeMo Agent Toolkit to connect natively to the life sciences models and libraries in BioNeMo, including Evo 2, Boltz-2, and OpenFold3. See the new desktop app in action below: The app is compatible with Pro, Max, Team, and Enterprise plans. Anthropic has detailed documentation all about the new Claude Science desktop app available here. You can learn more about Claude Science app and find the download link here.

Anthropic launches "AI workbench" for scientists using Claude

Claude Science aims to be a unified research package for scientists * Claude Science is a new "workbench" to consolidate fragmented research workflows * Everything from literature review to publication is handled on private infrastructure * Anthropic continues to roll out industry-specific AI tools for real-world use cases Anthropic has introduced Claude Science - a new, beta AI workbench it says will let scientists consolidate fragmented research workflows into one unified environment. With model capabilities no longer holding back AI adoption, the Claude-maker's solution is to respond to today's challenges, including limited use cases, struggles deploying AI in real-world environments and difficulties integrating multiple tools. Claude Science represents this response, packaging existing capabilities into a purpose-built application for life sciences and scientific computing, following earlier work on MCPs, skills and other partnerships. An FAQ on Claude Science's web page reiterates this: "Claude Science is a public beta app, not a model." Scientific 'workbench' Anthropic's clearest message in the announcement is that scientific research is largely held back by workflow fragmentation, not model intelligence, with scientists already juggling tools like PubMed, Jupyter, R, a cluster terminal and more. "Claude Science brings these fragmented tools into a single research environment where scientists can conduct all stages of their work," the company summarized. The platform should help scientists handle everything, from literature review and hypothesis exploration to analysis, figure generation, manuscript drafting and publication. "Scientific research is inherently visual," Anthropic wrote, acknowledging that many researchers are being held back in quickly and accurately producing visuals, which could need multiple revisions and finetunes before reaching production. For full auditability, Claude Science also includes underlying source code, message history and plain-language explanations within AI-generated outputs for scientists to review and audit progress. "It runs on your lab's own infrastructure," Anthropic added, referencing enterprise-grade laptops, Linux boxes or HPC login nodes, "so large or sensitive datasets never have to leave the systems they're already on, and only the context needed for each step of the analysis is sent to Claude Science is a growing focus for AI developers Anthropic says early testers have already used Claude Science for single-cell RNA sequencing analysis, CRISPR screen design, protein structure prediction and cheminformatics, by the likes of Manifold Bio, Allen Institute neuroscientist Jérôme Lecoq, and UCSF Brain Tumor Center associate professor and epidemiologist Stephen Francis. The new tool represents a growing area of interest for AI developers, who are now targeting sectors with industry-specific tools rather than continually upgrading model capabilities without offering clear use cases. Until now, finance and legal have been a major focus for the likes of Anthropic and OpenAI, and this new science-focused initiative could mark the next stage. It follows rival company OpenAI's introduction of Prism earlier this year, described as an "AI-native workspace for scientists to write and collaborate on research" that launched with GPT-5.2 - the then-current model. Claude Science is a separate app that's available in beta for macOS and Linux installations to Pro, Max, Team and Enterprise subscribers. The company has also committed up to $30,000 in credits for 50 lucky projects. Follow TechRadar on Google News and add us as a preferred source to get our expert news, reviews, and opinion in your feeds.

Anthropic launches Claude Science app for researchers and scientists

The company said it wanted to remove the tedious procedural aspects inherent to scientific research by uniting fragmented tools, resources, file formats and databases. Anthropic, the AI company behind Claude and Mythos, has unveiled its 'Claude Science' offering, which it described as "an AI workbench for scientists". Classified as a "public beta app" that runs using existing Claude models, Anthropic said its new product would "integrate the tools and packages that researchers most commonly use" in order to produce "auditable artifacts", and provide "flexible access to computing resources". The company said it aimed to remove the tedious procedural aspects inherent to scientific research by uniting fragmented tools, resources, file formats and databases "into a single research environment where scientists can conduct all stages of their work". The app, which is now available in beta via Claude Pro, Max, Team and Enterprise plans, can help scientific users analyse literature, execute multi-step research, produce detailed artifacts, and iteratively refine figures and manuscripts prior to publication, according to its maker. Anthropic, in a blogpost detailing the release, said that Claude Science can natively render "rich scientific artifacts, including 3D protein structures, genome browser tracks, chemical structures and more", alongside generated plain-language descriptions of how such figures were created, to be used for later validation, record-keeping and reproduction. The app can also handle planning and resource allocation for large-scale analyses that would typically require separate monitoring and computing capacity decisions to be made by a researcher or team, according to Anthropic. "As the pipeline runs, a reviewer agent inspects the outputs, flagging incorrect citations, untraceable numbers and figures that don't match their underlying code, and self-correcting as it goes," the blogpost read. The app is also said to be capable of synthesising answers to user questions through consultation of a wide range of databases and trusted sources of scientific information, which can be customised to user preferences. Anthropic noted that in recent months, researchers have used Claude Science in beta for tasks such as single-cell RNA sequencing analysis, protein structure prediction, cheminformatics and more. Meanwhile, Bloomberg reported that Anthropic has started to work on in-house, preclinical drug discovery schemes outside of the traditional scope of biotech and pharma research. Earlier this week, Google Cloud Marketplace said it would begin offering two 'large quantitative models' (LQMs) developed by SandboxAQ later in 2026 with the aim of driving AI-assisted developments in materials science, healthcare and drug discovery. SandboxAQ is already integrated with Anthropic's Claude AI model. It claims its LQMs can offer "critical advances" in sectors such as life sciences, financial services and navigation. Yesterday, after weeks of uncertainty around the status and availability of Claude Fable 5 and Mythos 5 due to an impasse between the US government and Anthropic, the AI models had their export bans lifted by the country's Department of Commerce. Don't miss out on the knowledge you need to succeed. Sign up for the Daily Brief, Silicon Republic's digest of need-to-know sci-tech news.

5 takeaways from Anthropic's big science event

On June 30, at an Anthropic event in San Francisco called "The Briefing: AI for Science," Amodei didn't declare that AI's impact on biology and other sciences had unleashed that effect, or was about to pull it off. Instead, he emphasized that he doesn't expect it to transpire in the next couple of years. He floated that it "might" happen a decade from now. In AI, 2036 feels like the incredibly distant future. But the point of Anthropic's event was to make the case that the company is working toward the compression that Amodei wrote about. In particular, it unveiled Claude Science, a new version of Claude, tuned for scientific research, that's launching in beta today. Alexander Tarashansky, who led development of the product, did an extended on-stage demo. Most of the remainder of the event was dedicated to panel discussions, with participants including Amodei, GLP-1 drug inventor Lotte Knudsen, Bristol Myers Squibb CEO Chris Boerner, Novartis CEO Vas Narasimhan, and Genentech executive VP Aviv Regev.

Anthropic launches Claude Science workbench for researchers

Anthropic introduced Claude Science on Tuesday, an AI workbench aimed at facilitating computational research for scientists by consolidating various databases, pipelines, and tools into a single environment. The company clarified that Claude Science is "not a new AI model and not a more capable model for biology," as it operates on existing Claude models, including Claude Opus 4.8, without special access or gating. The launch builds on the earlier introduction of Claude for Life Sciences in October 2025, which enhanced the Claude chatbot's capabilities for life sciences tasks. The announcement was made during an AI for Science briefing, reflecting Anthropic's strategy to expand beyond just providing models to creating workflows tailored for specific industries. Claude Science features a primary AI assistant that functions as a project manager, linking to over 60 scientific databases. It includes prebuilt toolkits for disciplines such as genomics, protein structure, and chemistry. This assistant can create sub-assistants to delegate tasks effectively, allowing users to transfer work to customized expert assistants built for specific research needs. A separate fact-checker AI is used to verify citations and calculations before publication. This verification process addresses concerns about fabricated citations in AI-generated writing, although it still uses the same underlying model for checking. To promote reproducibility, Claude Science allows users to generate figures alongside their corresponding code, providing details about the environment used and explanations of how the figures were created. The platform is designed to save researchers time by enabling computations on their own infrastructure as opposed to relying on Anthropic's servers. Early adopters include Jérôme Lecoq of the Allen Institute, who utilized Claude Science to develop a multi-agent computational review pipeline, and Stephen Francis's team at UCSF, which expedited germline analysis of glioma significantly. The launch comes shortly after OpenAI released GPT-Rosalind -- a model tailored for biological reasoning -- in April. OpenAI's offering was gated to qualified enterprise customers, contrasting with Anthropic's broader subscription model. Additionally, Google DeepMind approaches the market differently, providing proprietary foundational science models like AlphaFold. Anthropic intends to support up to 50 Claude Science projects with grants of up to $30,000, specifically targeting postdoctoral and graduate research initiatives across multiple domains. Applications will be accepted until July 15, 2026, and projects are scheduled to run from September 1 to December 1, 2026.

The New Anthropic Tool That Could Change How Drugs Are Developed

The launch marks the frontier AI lab's most significant move yet into life sciences. Anthropic says Claude Science integrates more than 60 preconfigured tools and connectors into "a single research environment" and provides access to local, remote, and high-performance computing resources. "AI has the potential to dramatically accelerate the pace of scientific discovery and the development of healthcare interventions," the company said in a statement on its website. Claude Science, currently in beta testing, is available for Claude Pro, Max, Team, and Enterprise users on macOS and Linux.

Anthropic unveils 'Claude Science' AI platform for scientific research

The launch is part of Anthropic's ⁠life sciences ⁠and healthcare initiative, which the IPO-bound company has been developing since October 2025. Anthropic on Tuesday launched Claude Science, an AI platform designed to help scientists streamline research, analyze data and manage complex computing workflows. The launch is part of Anthropic's ⁠life sciences ⁠and healthcare initiative, which the IPO-bound company has been developing since October 2025. Here are a few details on the launch: Claude Science combines databases, coding tools, compute and research ⁠workflows in one workspace, helping scientists analyze literature, run analyses, create ⁠figures and manuscripts, and trace results back to their source code and environment. The tool is pre-configured with more than 60 scientific databases and can render scientific artifacts such as 3D protein structures, genome browser tracks and chemistry drawings, Anthropic said. Claude Science runs on Anthropic's ⁠existing Claude models, which have undergone the company's standard responsible scaling and biosecurity evaluations. Several research organizations and companies testing the platform in beta reported significant efficiency gains, Anthropic added.

Anthropic launches Claude Science workbench for researchers By Investing.com

Investing.com - Anthropic released Claude Science on Tuesday, an AI workbench designed to consolidate scientific research tools into a single environment for conducting literature analysis, executing multistep research, and producing auditable artifacts. The app integrates over 60 curated skills and connectors pre-configured for genomics, single-cell analysis, proteomics, structural biology, and cheminformatics. Claude Science runs on macOS and Linux systems and connects to remote machines over SSH or HPC login nodes. The platform generates figures and manuscripts alongside the code that created them and natively renders 3D protein structures, genome browser tracks, and chemical structures. The workbench manages computing resources by drafting plans and submitting jobs to existing HPC clusters or Modal accounts, scaling analysis from a single GPU to hundreds as needed. A reviewer agent inspects outputs to flag incorrect citations, untraceable numbers, and figures that don't match underlying code. The system uses skills from NVIDIA's BioNeMo Agent Toolkit to connect to life sciences models including Evo 2, Boltz-2, and OpenFold3. Manifold Bio used Claude Science to nominate targets for experiments by assessing surface expression, trafficking, and safety for each tissue and target. Jérôme Lecoq at the Allen Institute built a multi-agent computational review template that reads thousands of papers and constructs narrative reviews with quantitative cross-study figures. Stephen Francis at the UCSF Brain Tumor Center used the app for molecular epidemiology studies on glioma, completing comprehensive germline workups in one-tenth the previous time. The beta version is available to Claude Pro, Max, Team, and Enterprise users. Anthropic will support up to 50 AI for Science projects with up to $30,000 in credits, with applications open through July 15, 2026, and award notifications by July 31. This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Anthropic launches AI drug discovery project: neglected diseases first

Claude Science targets preclinical genomics with links to 60 databases Anthropic launched its drug discovery program today. It's a clear move into neglected-disease research, and it also introduces Claude Science, the company's workbench for genomics, proteomics, and single-cell analysis. The company is moving past selling tools to labs and into preclinical discovery itself. Anthropic's argument is that this stage fits AI unusually well: biology data is abundant, simulation and ranking can happen quickly, and failures cost less here than they do later in the process. If that plays out, early medicine development could speed up, and the work could feed back into better life-sciences products. There's a different business model here too. Anthropic says its public benefit corporation structure gives it room to put patients' needs ahead of short-term returns. That comes at a moment when Novartis CEO Vas Narasimhan has said these tools could cut timelines from about 12 years to 7 or 8, while pushing success rates from roughly 8% to 16%. Anthropic also says Claude Science connects to more than 60 databases. In its early examples, a University of California, San Francisco researcher spotted viral contamination in minutes after it had been missed for a year, and another analysis covered 100 rare genetic diseases in under an hour and surfaced 32 follow-up candidates. If you follow AI in biotech, this deserves a close look. Discovery is still only the first part. Clinical trials cost come after that. You can get Claude Science through Anthropic's research offering, and Anthropic's new drug program is starting with preclinical work.

Anthropic Claude Science explained: An AI lab bench that lives inside your terminal

Anthropic has released Claude Science, which is essentially a workbench for AI researchers that tackles one of the least glamorous aspects of scientific research - the sheer burden of administration. In scientific research, there are many databases each having different schemas, incompatible file formats which require special pipelines and special viewers and jumping from tool to tool such as PubMed, Jupyter, R, and even the cluster terminal. All of this is combined into one in Claude Science. Also read: Claude Sonnet 5 vs Opus 4.8: Is the flagship model still worth paying for It can be used both locally on macOS and Linux or remotely using SSH or HPC login node similar to how Jupyter Notebook is used. The heart of it consists of a general purpose coordinating agent which has access to over 60 skills and connectors that have been configured for genomics, single cell analysis, proteomics, structural biology, cheminformatics and many other topics. These agents themselves can create sub-agents and a special reviewing agent ensures correct citations and computations. There are two important aspects of Claude Science. First, everything is reproducible as all figures are delivered with the precise code and environment which were used to generate the figure, its description in simple language how it was done and the whole message history, so that months later one can verify the result. In addition, a scientist can ask the agent to adjust some aspects of the figure like removing grid lines or applying log-scale using natural language. Also read: Fable 5, Mythos 5 coming back: Anthropic still hasn't answered key question Second, Claude Science computes by itself. It creates the computational plan, gets an approval before using any new resources and gives an opportunity for researchers to review or revoke any action before submitting a job to their lab's HPC cluster or Modal account for on-demand computation, from 1 GPU to hundreds, as required. Confidential data do not need to be transferred outside of the current infrastructure, because only the context necessary for each step of the analysis is being transferred to Claude. As a unique feature, Claude Science uses NVIDIA BioNeMo Agent Toolkit to natively connect to life science models Evo 2, Boltz-2 and OpenFold3. Examples of early adopters provide an idea of the variety. The biotech company Manifold Bio leveraged Claude Science for the nomination of drug targets for tissue-specific drugs using evaluation of surface expression, trafficking, and safety among other candidates. In the Allen Institute, Jérôme Lecoq (neuroscientist) has developed a 20-skills multi-agent pipeline that writes long-form literature reviews and reduces what would normally take up to two years into a matter of hours; it has so far written around 10 literature reviews, some more than 100 pages long. And at UCSF, the epidemiologist Stephen Francis employed it to accelerate glioma genetics to one-tenth of its earlier time, with validation from his lab of the results. Claude Science is available in its beta version to Pro, Max, Team, and Enterprise customers on macOs and Linux systems, with reduced Team license prices for academic and non-profit laboratories and grants of up to $30,000 in credits for up to 50 AI for science projects selected, application for which closes July 15th.